Fertility preservation parameters in patients with haematologic malignancy: a systematic review and meta-analysis

Tamar Katzir, Guy Shrem, Dror Meirow, Elad Berkowitz, Shai Elizur, Shlomi Cohen, Yechiel Burke, Meir Retchkiman, Alexander Volodarsky-Perel*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Patients with haematologic malignancies represent one of the most common groups referred for fertility preservation before gonadotoxic oncological treatment. The aim of this systematic review and meta-analysis was to evaluate the effect of haematologic cancer on ovarian reserve and response to ovarian stimulation compared with healthy controls. A total of eight observative studies were included in the final quantitative analysis. Despite a younger age (mean difference –4.17, 95% CI –6.20 to –2.14; P < 0.0001), patients with haematologic malignancy had lower serum anti-Müllerian hormone levels compared with the control group (MD –1.04, 95% CI –1.80 to –0.29; P = 0.007). The marginally higher total recombinant FSH dose (MD 632.32, 95% CI –187.60 to 1452.24; P = 0.13) and significantly lower peak oestradiol serum level (MD –994.05, 95% CI –1962.09 to –26.02; P = 0.04) were demonstrated in the study group compared with the healthy controls. A similar number of retrieved oocytes were achieved in both groups (MD 0.20, 95% CI –0.80 to 1.20; P = 0.69). In conclusion, haematologic malignancies may detrimentally affect ovarian function manifesting in decreased AMH serum levels despite a younger age compared with healthy controls. This effect can be overcome by the application of relevant IVF protocols and stimulation doses to achieve an adequate oocyte yield.

Original languageEnglish
Article number103978
JournalReproductive BioMedicine Online
Issue number2
StatePublished - Aug 2024


  • Fertility preservation
  • Hematologic malignancy
  • Oocyte cryopreservation
  • Ovarian stimulation
  • anti-Müllerian hormone


Dive into the research topics of 'Fertility preservation parameters in patients with haematologic malignancy: a systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this